2022年6月8日 · Whether the potential synergy between dose-dense paclitaxel and bevacizumab seen in the setting of platinum-resistant recurrent ovarian cancer will improve outcomes in first-line treatment is being investigated in the ICON8B trial.

The ICON8B study found that giving bevacizumab and weekly chemotherapy (Group 3) was more effective at preventing the cancer coming back or getting worse compared to the standard chemotherapy with bevacizumab (Group 1).

ICON8B, a 3-arm trial, compared BEV+q3wCT versus (vs) BEV+q3wCddwT vs q3wCddwT in high-risk stage III (residual disease >1cm diameter after primary surgery or requirement for primary chemotherapy) and stage IV EOC.

2019年9月22日 · ICON8B. A phase 3 randomised trial investigating the combination of dose-fractionated chemotherapy and bevacizumab compared to either strategy alone for the first-line treatment of women with newly diagnosed high-risk stage III-IV epithelial ovarian, fallopian tube or primary peritoneal cancer

#159 ICON8B: GCIG phase III randomised trial comparing weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy+ bevacizumab in first-line high-risk stage III-IV epithelial ovarian cancer treatment: primary progression-free survival analysis

Methods: In this open-label, randomised, controlled, phase 3 trial (ICON8), women aged 18 years or older with newly diagnosed stage IC-IV epithelial ovarian, primary peritoneal, or fallopian tube carcinoma (here collectively termed ovarian cancer, as defined by International Federation of Gynecology and Obstetrics [FIGO] 1988 criteria) and an Ea...

ICON8 is a 3-arm trial, comparing standard q3w CT with dose-dense q1w regimens in a predominantly European patient group. Methods: Eligible women with FIGO stage IcG3- IV EOC were randomised 1:1:1 to Arm 1 (standard) - q3w C AUC5/6 + q3w T 175mg/m 2; Arm 2 - q3w C AUC5/6 + q1w T 80mg/m 2; Arm 3 - q1w C AUC2 + q1w T 80 mg/m 2.

icon8/icon8b An international phase III randomised trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy, following immediate primary surgery or as part of delayed primary surgery, for women with newly diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer

ICON8B is a randomised two-arm, Gynaecologic Cancer Intergroup (GCIG) phase III trial investigating the combination of dose-fractionated chemotherapy and bevacizumab compared to either strategy alone for the first-line treatment of women with newly diagnosed high-risk stage III-IV epithelial ovarian, fallopian tube or primary peritoneal cancer.

ICON8B: A trial of chemotherapy and bevacizumab in ovarian cancer. Trial at a glance. Closed trial. Cancer type: Epithelial – high-grade serous and endometrioid; Treatment stage: Primary treatment; Acronym: ICON8B